Indian Courts Strengthen Patent Opposition Framework in High-Profile Cancer Immunotherapy and Drug Delivery Cases
Key Insights
The Madras High Court dismissed a writ petition by E.R. Squibb & Sons LLC (search) and Ono Pharmaceuticals challenging a Patent Opposition Board recommendation against their PD-1 (search) cancer immunotherapy patent, ruling that such recommendations are intermediate steps not subject to judicial review before final orders.
The Bombay High Court set aside a Controller's order in a curcumin pharmaceutical patent opposition case, emphasizing that patent authorities must provide reasoned decisions rather than bare conclusions when adjudicating post-grant oppositions.
Both rulings reinforce the statutory framework of India's patent opposition system, with the Madras court preventing premature judicial intervention while the Bombay court ensuring proper application of mind by patent authorities.
Two recent High Court decisions have clarified critical aspects of India's post-grant patent opposition framework, addressing both the limits of judicial intervention and the mandatory requirements for reasoned decision-making by patent authorities.
Madras High Court Reinforces Opposition Process Integrity
In a significant ruling involving a breakthrough cancer immunotherapy patent, the Madras High Court dismissed a writ petition filed by E.R. Squibb & Sons LLC (search) and Ono Pharmaceuticals Co. Ltd. (search) challenging a Patent Opposition Board recommendation. The case centered on Indian Patent No. IN340060, titled "Human Monoclonal Antibodies (search) to Programmed Death 1 (search) (PD-1 (search)) for Use in Cancer," which relates to antibody-based cancer therapies now central to modern oncology.
Zydus Healthcare Limited had filed a post-grant opposition under Section 25(2) of the Patents Act, 1970, challenging the validity of the patent. The Opposition Board subsequently recommended revocation, finding the patent lacking in novelty, inventive step, sufficiency, and clarity. Squibb and Ono argued that the Board had ignored key evidence, including expert affidavits addressing secondary considerations such as long-felt need, commercial success, and regulatory approvals in 64 countries.
The court held that Opposition Board recommendations are intermediate steps in the statutory process, not final orders subject to judicial review. "The Opposition Board recommendation is a step in a process, not an end in itself," the court observed, noting that it is explicitly not binding on the Controller. The ruling emphasized that the Controller retains full authority to accept, reject, or disregard the Board's recommendation after conducting an independent hearing.
Procedural Safeguards Remain Intact
The Madras High Court rejected arguments that procedural irregularities warranted immediate intervention, finding that the hearing before the Controller under Rule 62 is not a mere formality. The court reasoned that the Controller can examine whether the Board considered all evidence, require Board members to clarify their reasoning, and independently evaluate the recommendation's soundness.
"The petitioners had a full opportunity to raise every objection, including non-consideration of their expert evidence, the alleged procedural defect in admitting the Rule 59 rejoinder, and the absence of a date on the recommendation, before the Controller," the court stated. Section 117A of the Patents Act provides a statutory right of appeal against the Controller's final order, ensuring that any error in the post-grant opposition process remains capable of correction.
Bombay High Court Demands Reasoned Decision-Making
In a separate case involving pharmaceutical patent opposition, the Bombay High Court addressed the fundamental requirement for reasoned orders by patent authorities. Saurabh Arora, co-inventor of an earlier drug delivery patent application, had filed a post-grant opposition challenging a curcumin pharmaceutical patent granted to Cadila Pharmaceuticals.
The opposition was based on Arora's earlier application having a priority date of May 31, 2010, which pre-dated the challenged patent's priority of September 15, 2010. After five years of proceedings, the Deputy Controller dismissed the opposition with a bare conclusion that the prior art document was "not found an appropriate document within the meaning of Section 25(2)(c)," providing no reasoning for this determination.
Complete Absence of Reasoning Invalidates Order
The Bombay High Court set aside the Controller's order, emphasizing that the absence of reasoning constituted complete non-application of mind. "This was not inadequate reasoning, it was the absence of reasoning," the court observed, citing established precedents that reasons are the foundation of quasi-judicial adjudication.
The court noted that while the Controller acknowledged every relevant fact, including the undisputed priority dates, no explanation was provided for concluding that the prior art was inappropriate. "Where a Controller acknowledges every relevant fact and then offers no reasoning for its conclusion, the result is complete non-application of mind," the court stated.
Matter Remanded for Fresh Adjudication
Rather than deciding the opposition on merits, the Bombay High Court remanded the matter to a different Controller for fresh adjudication. The court rejected Cadila's argument that the appellate court should resolve the issue directly, noting that the appellate court's discretion to decide on merits exists only where the original authority has produced reasoning that can be examined.
"Deciding the opposition afresh would mean the Bombay High Court would be exercising original jurisdiction in place of the Controller, thereby effectively permitting the Controller to abdicate its statutory duty under the Patents Act," the court reasoned.
Implications for Patent Practice
Both decisions reinforce different aspects of India's patent opposition framework. The Madras High Court ruling prevents premature judicial intervention in ongoing opposition proceedings, while the Bombay High Court decision ensures that patent authorities cannot substitute unexplained conclusions for the reasoned analysis the statute demands.
The rulings collectively emphasize that while the patent opposition system includes multiple procedural safeguards and appeal mechanisms, these must be utilized in the proper sequence. Patent authorities retain significant responsibility to provide substantive reasoning for their decisions, while parties must exhaust statutory remedies before seeking judicial intervention.
For pharmaceutical companies and patent practitioners, these decisions clarify that opposition proceedings must be allowed to run their full course through the statutory framework, while also ensuring that patent authorities cannot avoid their duty to provide reasoned analysis of complex technical and legal issues.